ACIR

Adams et al. identified Etv3 as a dendritic cell-intrinsic regulator of immune tolerance. Etv3 is induced during DC maturation and expressed in tissue-derived migratory DCs (migDCs). bit.ly/40tywaz  

Genetic studies by Li et al. showed that SLAMF6 (also known as Ly108) functioned to repress T cell activation in mice and humans by triggering homotypic cis interactions at the T cell surface, suppressing TCR signaling through SHP-1 and limiting antitumor immunity [...] bit.ly/4cMNik4

To support more sensitive immunopeptidomics analyses, Manakongtreecheep and Ctortecka et al. developed Pepyrus to rapidly and scalably generate user-defined peptide libraries in E. coli that could provide chromatographic and spectral references. bit.ly/3MIGzNI  

Huff et al. investigated a pooled peptide vaccine covering six KRAS mutations, plus ipilimumab and nivolumab in resected PDAC. mKRAS-specific T cell responses emerged in 11/12 patients, and 4/12 remained disease-free at ~36 months. bit.ly/3OxJUzH

Using scRNA- and scTCRseq profiling, Coppola and Kerr et al. showed that large changes were induced during ex vivo expansion of TIL samples from six patients with metastatic melanoma. bit.ly/46oFYr3

Chen et al. designed an overnight 16h fasting regimen that augmented ICB efficacy in mice and patients with colorectal cancer. Fasting reprogrammed tumor cell nutrient preferences, triggering a metabolic trade-off that enriched intratumoral isoleucine (Ile). bit.ly/4tLLWfA

Flt3L boosts ICB therapy. bit.ly/4cTrt2i  

Le et al. showed that following attenuated Plasmodium sporozoite vaccination, WT, but not TCRγδ KO mice accumulated antigen-specific T cells in their livers and spleens. bit.ly/4rq8n8I   @thedohertyinst.bsky.social

Marceaux et al. performed spatial multi-omics analysis across clinically annotated LUAD and LUSC cohorts of NSCLC, and stratified it into lymphoid-, myeloid-, and mixed-enriched subtypes, independent of driver mutations. CD14⁺CD4⁺ T cells [...] bit.ly/4rnmUSh  @wehi-research.bsky.social

Based on the randomized phase 3 LungTIME-C01 trial, Huang et al. reported that early time of day (ToD) treatment (before 3 pm) for the first 4 doses improved anti-PD-1 efficacy compared with late ToD treatment (after 3 pm) in patients with stage IIIC–IV NSCLC. bit.ly/4rWdKfB

Peng, Yang, Antonopoulou, et al. found that in human PDAC, high expression of GATA6 correlated with increased MHC-I expression, immune cell infiltration, and interactions with CD8+ T cells. bit.ly/46c1LCd  

Focused on key challenges of CD19 CAR T cell therapy, such as on-target/off-tumor healthy B cell depletion and antigen-negative escape and relapse, Cohen, Bochi-­Layec and Lemoine et al. developed CAR T cells targeting the BCR-carrying IGHV-34 (CART4-34), which is [...] bit.ly/403aFyB

Becilli, Metzler, Bracaglia et al. treated 8 children with severe/refractory autoimmune diseases (AD) with one dose of CD19 CAR T cells to reset the dysregulated immune system. bit.ly/4c2Ph3x

Oncolytic viral therapy induces deep T cell infiltration and persistent activation against glioblastoma, likely through epitope spread bit.ly/4qHQuAY  @danafarber.bsky.social

Liang and Zeng et al. showed that small-molecule tyrosine kinase inhibitor DCC-2036 repolarized TAMs from an “M2” to an “M1” phenotype and enhanced antitumor CD8+ T cell immunity in a 4T1 TNBC tumor model. bit.ly/460aFCG

Gao, Peng, Cheng, Zhang, et al. found that surgically blocking the meningeal blood vessel hindered GBM progression in mice by restricting access to the dura mater by circulation-derived border-associated macrophages (cBAM). bit.ly/3O8Iag6

👉 Another card from Doug: An updated and expanded review on the Hallmarks of Cancer doi.org/10.1016/j.ce...

⁉️ Are we there yet (on immunogenic peptide predictions)?- No doi.org/10.1136/jitc...

We are looking forward to meeting our readers at #AACRIO26 next week. Come and say Hi! at our table.

Based on shifted Poisson statistics, Salazar-Cavazos et al. developed the StoICS pipeline and found that stochastic activation of rare “spark T cells” accounts for variable cancer immunotherapy outcomes, even when immunological settings appear identical. bit.ly/4rO4Sc0  

Zhang, Wang, Xiao, Liu et al. focused on the role of perineural invasion in the TME of triple negative breast cancer (TNBC). bit.ly/4kszOvH

Haften and Sluis et al. showed that transient cell cycle arrest activated CD8⁺ T cells into a metabolically primed, IL-2-producing effector state that supported rapid proliferation and enhanced antitumor activity after release. bit.ly/4rfLoNx   @unileiden.bsky.social

Santiago-Carvalho et al. identified the extracellular ATP sensor P2RX7 as a poor prognostic factor in NSCLC that was highly enriched in Tregs. In mouse models, Treg-specific KO of P2RX7 reduced lung tumor burden, without altering Treg numbers. bit.ly/4quiPdW   @mayocliniccancer.bsky.social

Three recent clinical trials evaluated different strategies for improving immune checkpoint blockade bit.ly/4ctR1mq  @chumontreal.bsky.social

Gaglione et al. developed TCRAFT, a pooled synthesis method to rapidly assemble large TCR libraries (>104) with high accuracy (>99%) and native ɑ/β chain pairing. bit.ly/4auFHVU

Using LNP-encapsulated mRNA vaccines encoding HA or NP flu model CD4+ T cell antigens, Rood et al. showed that murine APCs that directly produced antigen in vitro or after IM vaccination of mice are the optimal APCs for activating T cells in vitro. bit.ly/4bByG6G  

🤝 A little help from your friends - allogeneic iNKT cells form immune activating complexes with DCs doi.org/10.1158/2326...

🚪 Something big is at your door! - A review on the potential of shared TAAs to prevent cancer doi.org/10.1136/jitc...

Govindarajan and Mejia-Guerrero et al. used enrichment of N-glycosylated surface proteins and mass spectrometry to profile 85 patient-derived xenografts and generated Glyco PDXplorer, an in vivo pan-cancer atlas of tumor cell-surface N-glycoproteins. bit.ly/4tiw4RE  

Decker et al. compared TCR-T (expressing true TCR) and CAR-T (expressing anti-pHLA Aab with CD28 or 4-1BB costimulation) targeting the same peptide antigen, MAGEA4. bit.ly/45NGgrj